KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBIT (2017 - 2026)

Aquestive Therapeutics has reported EBIT over the past 9 years, most recently at -$28.8 million for Q4 2025.

  • For Q4 2025, EBIT fell 112.38% year-over-year to -$28.8 million; the TTM value through Dec 2025 reached -$71.1 million, down 130.9%, while the annual FY2025 figure was -$71.1 million, 130.9% down from the prior year.
  • EBIT for Q4 2025 was -$28.8 million at Aquestive Therapeutics, down from -$11.5 million in the prior quarter.
  • Over five years, EBIT peaked at $55000.0 in Q2 2024 and troughed at -$28.8 million in Q4 2025.
  • A 5-year average of -$9.7 million and a median of -$8.9 million in 2022 define the central range for EBIT.
  • Biggest five-year swings in EBIT: soared 101.31% in 2024 and later crashed 20769.09% in 2025.
  • Year by year, EBIT stood at -$11.7 million in 2021, then increased by 8.19% to -$10.7 million in 2022, then surged by 63.49% to -$3.9 million in 2023, then crashed by 247.2% to -$13.6 million in 2024, then plummeted by 112.38% to -$28.8 million in 2025.
  • Business Quant data shows EBIT for AQST at -$28.8 million in Q4 2025, -$11.5 million in Q3 2025, and -$11.4 million in Q2 2025.